AAAAAA

   
Results: 1-25 | 26-27
Results: 1-25/27
Expression and activation of a C-terminal truncated isoform of STAT5 (STAT5 Delta) following interleukin 2 administration or AZT monotherapy in HIV-infected individuals
Authors: Bovolenta, C Camorali, L Mauri, M Ghezzi, S Nozza, S Tambussi, G Lazzarin, A Poli, G
Citation: C. Bovolenta et al., Expression and activation of a C-terminal truncated isoform of STAT5 (STAT5 Delta) following interleukin 2 administration or AZT monotherapy in HIV-infected individuals, CLIN IMMUNO, 99(1), 2001, pp. 75-81
Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor
Authors: Gianotti, N Tambussi, G Boeri, E Lazzarin, A
Citation: N. Gianotti et al., Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor, J BIOL REG, 15(2), 2001, pp. 166-169
Acute self-limiting hepatitis C after possible sexual exposure: Sequence analysis of the E-2 region of the infected patient and sexual partner
Authors: Morsica, G Sitia, G Bernardi, MT Tambussi, G Novati, R De Bona, A Gianotti, N Lazzarin, A
Citation: G. Morsica et al., Acute self-limiting hepatitis C after possible sexual exposure: Sequence analysis of the E-2 region of the infected patient and sexual partner, SC J IN DIS, 33(2), 2001, pp. 116-120
Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: A controlled study of 3 IL-2 regimens with antiviral drug therapy
Authors: Tambussi, G Ghezzi, S Nozza, S Vallanti, G Magenta, L Guffanti, M Brambilla, A Vicenzi, E Carrera, P Racca, S Soldini, L Gianotti, N Murone, M Veglia, F Poli, G Lazzarin, A
Citation: G. Tambussi et al., Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: A controlled study of 3 IL-2 regimens with antiviral drug therapy, J INFEC DIS, 183(10), 2001, pp. 1476-1484
Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid
Authors: Tambussi, G Gori, A Capiluppi, B Balotta, C Papagno, L Morandini, B Di Pietro, M Ciuffreda, D Saracco, A Lazzarin, A
Citation: G. Tambussi et al., Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid, CLIN INF D, 30(6), 2000, pp. 962-965
Viral dynamics and mutations in the pol gene during primary HIV-1 infection
Authors: Cenci, A Bertoli, A Tambussi, G Menzo, S Clementi, M Lazzarin, A Capiluppi, B Ciuffreda, D Forbici, F Aquaro, S Marcuccilli, F Calio, R Perno, CF
Citation: A. Cenci et al., Viral dynamics and mutations in the pol gene during primary HIV-1 infection, J BIOL REG, 14(1), 2000, pp. 7-10
Immunologic reconstitution by interleukin-2: facts and open questions
Authors: Vallanti, G Bovolenta, C Brambilla, A Tambussi, G Lazzarin, A Vicenzi, E Poli, G
Citation: G. Vallanti et al., Immunologic reconstitution by interleukin-2: facts and open questions, J BIOL REG, 14(1), 2000, pp. 41-44
Four drug-HAART in primary HIV-1 infection: clinical benefits and virologic parameters
Authors: Capiluppi, B Ciuffreda, D Quinzan, GP Sciandra, M Marroni, M Morandini, B Costigliola, P Guerra, L Di Pietro, M Fibbia, GF Visona, R Cusini, M Bressi, C Tambussi, G Lazzarin, A
Citation: B. Capiluppi et al., Four drug-HAART in primary HIV-1 infection: clinical benefits and virologic parameters, J BIOL REG, 14(1), 2000, pp. 58-62
Primary HIV infection: molecular approaches in diagnosis and monitoring
Authors: Ciuffreda, D Capiluppi, B Mastrorilli, E Balconi, G Tambussi, G Lazzarin, A Lillo, F
Citation: D. Ciuffreda et al., Primary HIV infection: molecular approaches in diagnosis and monitoring, J BIOL REG, 14(1), 2000, pp. 63-67
Early production of HIV-1 neutralising antibodies in patients following highly active antiretroviral treatment (HAART) during primary HIV infection
Authors: Barassi, C De Santis, C Pastori, C Marraccini, P Ciuffreda, D Capiluppi, B Bressi, C Siccardi, AG Lazzarin, A Tambussi, G Lopalco, L
Citation: C. Barassi et al., Early production of HIV-1 neutralising antibodies in patients following highly active antiretroviral treatment (HAART) during primary HIV infection, J BIOL REG, 14(1), 2000, pp. 68-74
Analysis of serum and plasma beta chemokines in primary HIV infection (PHI)
Authors: Malnati, MS Tambussi, G Fischetti, L Algeri, M Veglia, F Capiluppi, B Lazzarin, A Lusso, P
Citation: Ms. Malnati et al., Analysis of serum and plasma beta chemokines in primary HIV infection (PHI), J BIOL REG, 14(1), 2000, pp. 75-78
Cyclosporin A in combination with HAART in primary HIV-1 infection
Authors: Rizzardi, GP Vaccarezza, M Capiluppi, B Tambussi, G Lazzarin, A Pantaleo, G
Citation: Gp. Rizzardi et al., Cyclosporin A in combination with HAART in primary HIV-1 infection, J BIOL REG, 14(1), 2000, pp. 79-81
Hepatitis B surface antigen clearance and appearance of antibodies againsthepatitis B surface antigen after treatment with recombinant interleukin 2in a human immunodeficiency virus-infected patient
Authors: Gianotti, N Uberti-Foppa, C Boeri, E Marinelli, M Tambussi, G Finazzi, R Lazzarin, A
Citation: N. Gianotti et al., Hepatitis B surface antigen clearance and appearance of antibodies againsthepatitis B surface antigen after treatment with recombinant interleukin 2in a human immunodeficiency virus-infected patient, HEPATOLOGY, 32(6), 2000, pp. 1409-1410
Effects of hydroxyurea on T cell count changes during primary HIV infection
Authors: Ravot, E Tambussi, G Jessen, H Tinelli, C Lazzarin, A Lisziewicz, J Lori, F
Citation: E. Ravot et al., Effects of hydroxyurea on T cell count changes during primary HIV infection, AIDS, 14(5), 2000, pp. 619-622
Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count
Authors: Rizzardi, GP Tambussi, G Bart, PA Chapuis, AG Lazzarin, A Pantaleo, G
Citation: Gp. Rizzardi et al., Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count, AIDS, 14(15), 2000, pp. 2257-2263
Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy
Authors: Bart, PA Rizzardi, GP Tambussi, G Chave, JP Chapuis, AG Graziois, C Corpataux, JM Halkic, N Meuwly, JY Munoz, M Meylan, P Spreen, W McDade, H Yerly, S Perrin, L Lazzarin, A Pantaleo, G
Citation: Pa. Bart et al., Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy, AIDS, 14(13), 2000, pp. 1887-1897
Metabolic disorders in a cohort of patients treated with highly aggressiveantiretroviral therapies during primary HIV-1 infection
Authors: Capiluppi, B Ciuffreda, D Sciandra, M Marroni, M Tambussi, G Lazzarin, A
Citation: B. Capiluppi et al., Metabolic disorders in a cohort of patients treated with highly aggressiveantiretroviral therapies during primary HIV-1 infection, AIDS, 14(12), 2000, pp. 1861-1862
Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy
Authors: Fleury, S Rizzardi, GP Chapuis, A Tambussi, G Knabenhans, C Simeoni, E Meuwly, JY Corpataux, JM Lazzarin, A Miedema, F Pantaleo, G
Citation: S. Fleury et al., Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy, P NAS US, 97(10), 2000, pp. 5393-5398
CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro
Authors: Lopalco, L Barassi, C Pastori, C Longhi, R Burastero, SE Tambussi, G Mazzotta, F Lazzarin, A Clerici, M Siccardi, AG
Citation: L. Lopalco et al., CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro, J IMMUNOL, 164(6), 2000, pp. 3426-3433
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA
Authors: Rizzardi, GP De Boer, RJ Hoover, S Tambussi, G Chapuis, A Halkic, N Bart, PA Miller, V Staszewski, S Notermans, DW Perrin, L Fox, CH Lange, JMA Lazzarin, A Pantaleo, G
Citation: Gp. Rizzardi et al., Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA, J CLIN INV, 105(6), 2000, pp. 777-782
Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality
Authors: Soudeyns, H Campi, G Rizzardi, GP Lenge, C Demarest, JF Tambussi, G Lazzarin, A Kaufmann, D Casorati, G Corey, L Pantaleo, G
Citation: H. Soudeyns et al., Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality, BLOOD, 95(5), 2000, pp. 1743-1751
Study on mutations and antiretroviral therapy (SMART): preliminary results
Authors: Gianotti, N Moretti, F Tambussi, G Racca, S Presi, S Crucianelli, R Carrera, P Ferrari, M Lazzarin, A
Citation: N. Gianotti et al., Study on mutations and antiretroviral therapy (SMART): preliminary results, ANTIVIR TH, 4, 1999, pp. 65-69
The rationale for a study on HIV-1 reverse transcriptase mutations and outcome of antiretroviral therapy with two nucleoside analogs
Authors: Gianotti, N Moretti, F Tambussi, G Capiluppi, B Ferrari, M Lazzarin, A
Citation: N. Gianotti et al., The rationale for a study on HIV-1 reverse transcriptase mutations and outcome of antiretroviral therapy with two nucleoside analogs, J BIOL REG, 13(3), 1999, pp. 158-162
Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection
Authors: Lillo, FB Ciuffreda, D Veglia, F Capiluppi, B Mastrorilli, E Vergani, B Tambussi, G Lazzarin, A
Citation: Fb. Lillo et al., Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection, AIDS, 13(7), 1999, pp. 791-796
In vivo administration of recombinant IL-2 to individuals infected by HIV down-modulates the binding and expression of the transcription factors ying-yang-1 and leader binding protein-1/late simian virus 40 factor
Authors: Bovolenta, C Camorali, L Lorini, AL Vallanti, G Ghezzi, S Tambussi, G Lazzarin, A Poli, G
Citation: C. Bovolenta et al., In vivo administration of recombinant IL-2 to individuals infected by HIV down-modulates the binding and expression of the transcription factors ying-yang-1 and leader binding protein-1/late simian virus 40 factor, J IMMUNOL, 163(12), 1999, pp. 6892-6897
Risultati: 1-25 | 26-27